Vestal Point Capital LP Acquires 575,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Vestal Point Capital LP raised its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 50.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,725,000 shares of the company's stock after acquiring an additional 575,000 shares during the period. Structure Therapeutics makes up 2.8% of Vestal Point Capital LP's investment portfolio, making the stock its 11th largest position. Vestal Point Capital LP owned about 3.01% of Structure Therapeutics worth $46,782,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of GPCR. Deep Track Capital LP raised its holdings in shares of Structure Therapeutics by 129.4% in the 4th quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock valued at $75,936,000 after acquiring an additional 1,579,492 shares in the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $13,560,000. Marshall Wace LLP raised its holdings in shares of Structure Therapeutics by 339.6% in the 4th quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock valued at $15,817,000 after acquiring an additional 450,531 shares in the last quarter. Foresite Capital Management VI LLC purchased a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $11,390,000. Finally, Ameriprise Financial Inc. raised its holdings in shares of Structure Therapeutics by 29.4% in the 4th quarter. Ameriprise Financial Inc. now owns 1,420,052 shares of the company's stock valued at $38,512,000 after acquiring an additional 322,601 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

GPCR traded down $0.10 on Friday, hitting $24.55. 267,802 shares of the company were exchanged, compared to its average volume of 930,562. The firm has a fifty day simple moving average of $21.53 and a two-hundred day simple moving average of $26.02. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The stock has a market capitalization of $1.41 billion, a PE ratio of -33.18 and a beta of -1.69.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities analysts expect that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GPCR. Citigroup began coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price target on the stock. William Blair began coverage on Structure Therapeutics in a report on Friday, February 28th. They set an "outperform" rating on the stock. Finally, HC Wainwright decreased their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $79.86.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.